Sherwin Wu
Research Subjects
Research Interests
Sherwin Wu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amro Aboukameel
Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 732 HWCRC, 4100 John R Street, Detroit, Michigan 48201, USA
1 shared publication - Angela Sosin
Department of Oncology, Barbara Ann Karmanos Cancer Institute (KCI), Detroit, MI, 48201, USA
1 shared publication - Asfar Sohail Azmi
Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
1 shared publication - Ayad M. Al-Katib
Lymphoma Research Laboratory, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA
1 shared publication - Dajun Yang
Ascenta Therapeutics, Inc., Malvern, Pennsylvania, USA
1 shared publication - Jiusheng Wu
Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 732 HWCRC, 4100 John R Street, Detroit, Michigan 48201, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2009
- Published by Springer Nature in Molecular Cancer
- Vol. 8 (1) , 115
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction. It is closely related to MDM2 antagonists MI-219 and Nutlin-3 in terms of the expected working mechanisms. The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell follicular lymphoma line. For comparison purpose, MI-319, MI-219 and Nutlin-3 were assessed side by side against FSCCL and three other B-cell hematological tumor cell lines in growth inhibition and gene expression profiling experiments.
- 1 January 2009
- Published by Springer Nature in Molecular Cancer
- Vol. 8 (1) , 115
Open AccessAn MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction. It is closely related to MDM2 antagonists MI-219 and Nutlin-3 in terms of the expected working mechanisms. The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell follicular lymphoma line. For comparison purpose, MI-319, MI-219 and Nutlin-3 were assessed side by side against FSCCL and three other B-cell hematological tumor cell lines in growth inhibition and gene expression profiling experiments.